HCV-IN-7 

HCV-IN-7 is an orally active and potent pan-genotypic HCV NS5A inhibitor with IC₅₀s of 3-47 pM. HCV-IN-7 shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake. HCV-IN-7 has anti-viral activity^[1].

IC50: 3-47 pM (genotypic HCV NS5A)^[1]

HCV-IN-7 inhibits GT1b (IC₅₀=12 pM), GT2a (IC₅₀=5 pM), GT1a (IC₅₀=27 pM), GT3a (IC₅₀=47 pM), GT4a (IC₅₀=3 pM), GT6a (IC₅₀=28 pM)^[1].
HCV-IN-7 (10 µM) has 12%, 42%, 12% inhibition for CYP2D6, CYP2C9, CYP3A4, respectively^[1].
HCV-IN-7 (10 µM) has cytotoxicity of 14%, 22%, 36% in Huh7, HepG2 and HEK cells, respectively^[1].
HCV-IN-7 has a less complex central tricyclic core as novel and potent pan-genotypic NS5A inhibitors with good pharmacokinetic profile^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

HCV-IN-7 (iv; 1 mg/kg) has a T_1/2 of 2 hours, CL of 11 mL/min/kg, and a V_ss of 2 L/kg for rats^[1].
HCV-IN-7 (po; 10 mg/kg) has a C_max of 1 μM and an AUC_last of 6 μM for rats^[1].
HCV-IN-7 (iv; 1 mg/kg) has a T_1/2 of 4 hours, a CL of 6 mL/min/kg, and a V_ss of 2 L/kg for dog^[1].
HCV-IN-7 (po; 10 mg/kg) has a C_max of 5 μM and an AUC_last of 49 μM for dog^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

768.92

C₄₀H₄₈N₈O₆S

1449756-86-8

O=C([C@H](C(C)C)NC(OC)=O)N(CCC1)[C@@H]1C(N2)=NC=C2C3=CC(C=C4)=C(S3)C5=C4C=C(C6=CN=C([C@H]7N(C([C@H](C(C)C)NC(OC)=O)=O)CCC7)N6)C=C5

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ramdas V, et al. Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate. J Med Chem. 2019 Dec 12;62(23):10563-10582.  [Content Brief]